Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

Lucid Diagnostics Inc. (LUCD) Stock Forecast 2025 - AI Price Prediction & Analysis

Lucid Diagnostics Inc. (LUCD) AI Stock Price Forecast & Investment Analysis

Lucid Diagnostics Inc. Stock Price Chart and Technical Analysis

Loading Lucid Diagnostics Inc. interactive price chart and technical analysis...

Lucid Diagnostics Inc. (LUCD) - Comprehensive Stock Analysis & Investment Research

Deep dive into Lucid Diagnostics Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Lucid Diagnostics Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Lucid Diagnostics Inc.: Lucid Diagnostics Inc. operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

Lucid Diagnostics Inc. (Stock Symbol: LUCD) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 4 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Lucid Diagnostics Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Lucid Diagnostics Inc.: With $4M in annual revenue and -1069.9% net margin, the company demonstrates developing profitability.

Annual Revenue: $4 million generating a -1069.9% net profit margin .

Market Capitalization: $139 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -78.9% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Lucid Diagnostics Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Lucid Diagnostics Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Lucid Diagnostics Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Lucid Diagnostics Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Lucid Diagnostics Inc.: Market positioning analysis based on available financial and operational metrics.

Lucid Diagnostics Inc. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy -4.3% gross margin, indicating strong pricing power and operational efficiency.

Lucid Diagnostics Inc. (LUCD) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Lucid Diagnostics Inc. stock analysis.

Loading Lucid Diagnostics Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Lucid Diagnostics Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Lucid Diagnostics Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Lucid Diagnostics Inc.: With a P/E ratio of -0.60, the market sees the stock as potentially undervalued.

P/E Ratio -0.60x
P/B Ratio 5.37x
Market Cap $139M
EPS $-0.95
Book Value/Share $0.20
Revenue/Share $0.04
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Lucid Diagnostics Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Lucid Diagnostics Inc.: An ROE of -78.9% indicates room for improvement in shareholder value creation.

ROE -78.9%
ROA -59.1%
ROIC -75.3%
Gross Margin -4.3%
Operating Margin -1077.4%
Net Margin -1069.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Lucid Diagnostics Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Lucid Diagnostics Inc.: A current ratio of 3.71 indicates strong liquidity.

Current Ratio 3.71x
Quick Ratio 3.40x
D/E Ratio 0.03x
Financial Leverage 1.33x
Interest Coverage -41.6x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Lucid Diagnostics Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Lucid Diagnostics Inc.: Free cash flow of $-21M indicates cash challenges that need attention.

Operating Cash Flow $-20M
Free Cash Flow $-21M
Capital Spending $-1M
CapEx/Sales 145.3%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Lucid Diagnostics Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Lucid Diagnostics Inc.: An asset turnover of 0.01x suggests room for improvement in asset utilization.

Asset Turnover 0.01x
Receivables Turnover 7.7x
Inventory Turnover 2.9x
Fixed Assets Turnover 0.2x
Days Sales Outstanding 47 days
Days Inventory 127 days
Payables Period 1707 days
Cash Conversion Cycle -1533 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Lucid Diagnostics Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Lucid Diagnostics Inc.: With annual revenue of $4M, Lucid Diagnostics Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $4M
R&D Expense $6M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 84%
Cash & Short-term Investments 77%
Total Liabilities 25%
Accounts Receivable 0%
Inventory 1%
Dividend & Shareholder Information
Shares Outstanding 131M
Growth Metrics (YoY)
EPS Growth -159.9%

Latest Lucid Diagnostics Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Lucid Diagnostics Inc. (LUCD) stock price and investment outlook.

📰 We are currently updating our news feed for Lucid Diagnostics Inc.. Check back soon for the latest market analysis and company updates.

Lucid Diagnostics Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Lucid Diagnostics Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $13M x 1.6x
AEMD Unlock Forecast - 30 Days FREE Trial $3M -0.1x 0.6x
ALUR Unlock Forecast - 30 Days FREE Trial $12M -0.4x -0.3x
AMIX Unlock Forecast - 30 Days FREE Trial $6M x 1.0x
ANGO Unlock Forecast - 30 Days FREE Trial $560M -1.4x 3.1x
ANIK Unlock Forecast - 30 Days FREE Trial $141M -4.3x 1.0x
AORT Unlock Forecast - 30 Days FREE Trial $2089M -198.2x 4.8x
APYX Unlock Forecast - 30 Days FREE Trial $152M -3.5x 25.9x
ARAY Unlock Forecast - 30 Days FREE Trial $121M -9.9x 2.0x
ATEC Unlock Forecast - 30 Days FREE Trial $3178M -7.4x 276.2x
ATRC Unlock Forecast - 30 Days FREE Trial $1951M -39.6x 4.1x
AVHHL Unlock Forecast - 30 Days FREE Trial $22M x x
BAX Unlock Forecast - 30 Days FREE Trial $9530M -94.9x 1.3x
BBNX Unlock Forecast - 30 Days FREE Trial $1320M x 4.5x
BDX Unlock Forecast - 30 Days FREE Trial $55959M 33.4x 2.2x
BEAT Unlock Forecast - 30 Days FREE Trial $23M -5.7x 55.9x
BJDX Unlock Forecast - 30 Days FREE Trial $2M -0.5x 0.6x
BSX Unlock Forecast - 30 Days FREE Trial $145695M 52.0x 6.2x
BTCY Unlock Forecast - 30 Days FREE Trial $13M -2.7x -0.1x
BVS Unlock Forecast - 30 Days FREE Trial $497M 63.5x 3.0x
CARL Unlock Forecast - 30 Days FREE Trial $127M x 1.2x
CERS Unlock Forecast - 30 Days FREE Trial $389M -13.8x 6.3x
CLPT Unlock Forecast - 30 Days FREE Trial $387M -23.5x 24.4x
CODX Unlock Forecast - 30 Days FREE Trial $18M -0.7x 0.5x
CTSO Unlock Forecast - 30 Days FREE Trial $51M -1.8x 5.7x
CVRX Unlock Forecast - 30 Days FREE Trial $237M -5.5x 4.9x
DCTH Unlock Forecast - 30 Days FREE Trial $347M 289.4x 3.0x
DHAI Unlock Forecast - 30 Days FREE Trial $0M x -0.3x
DRIO Unlock Forecast - 30 Days FREE Trial $81M 0.6x 1.1x
DRTS Unlock Forecast - 30 Days FREE Trial $333M x 3.9x
DXCM Unlock Forecast - 30 Days FREE Trial $25541M 35.4x 9.4x
DYNT Unlock Forecast - 30 Days FREE Trial $1M -0.2x 0.2x
EBRCZ Unlock Forecast - 30 Days FREE Trial $450M x 11.6x
ECIA Unlock Forecast - 30 Days FREE Trial $3M x 1.8x
EMBC Unlock Forecast - 30 Days FREE Trial $681M 7.1x -0.8x
EMED Unlock Forecast - 30 Days FREE Trial $0M x x
FEMY Unlock Forecast - 30 Days FREE Trial $48M -1.4x 10.5x
FOFA Unlock Forecast - 30 Days FREE Trial $8M x 9.6x
GCTK Unlock Forecast - 30 Days FREE Trial $6M 0.9x 2.2x
GIPL Unlock Forecast - 30 Days FREE Trial $5M x 25.8x
GKOS Unlock Forecast - 30 Days FREE Trial $6227M -46.3x 8.1x
GMED Unlock Forecast - 30 Days FREE Trial $12501M 29.5x 2.8x
GUTS Unlock Forecast - 30 Days FREE Trial $111M x 13.8x
HAE Unlock Forecast - 30 Days FREE Trial $3924M 23.3x 4.6x
HRGN Unlock Forecast - 30 Days FREE Trial $32M x 20.6x
IART Unlock Forecast - 30 Days FREE Trial $1053M 200.2x 1.0x
ICCM Unlock Forecast - 30 Days FREE Trial $42M x 14.4x
ICU Unlock Forecast - 30 Days FREE Trial $11M -1.1x 0.9x
ICUI Unlock Forecast - 30 Days FREE Trial $3514M -49.8x 1.7x
IDXG Unlock Forecast - 30 Days FREE Trial $4M 0.8x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $27M x 6.3x
IINNW Unlock Forecast - 30 Days FREE Trial $8M x 1.9x
INBS Unlock Forecast - 30 Days FREE Trial $6M -0.3x 1.7x
INFU Unlock Forecast - 30 Days FREE Trial $189M 40.8x 3.4x
INSP Unlock Forecast - 30 Days FREE Trial $3975M 89.2x 6.0x
IRMD Unlock Forecast - 30 Days FREE Trial $1184M 55.9x 12.0x
IRTC Unlock Forecast - 30 Days FREE Trial $5744M -20.2x 47.1x
KIDS Unlock Forecast - 30 Days FREE Trial $425M -20.7x 1.2x
KMTS Unlock Forecast - 30 Days FREE Trial $1258M x x
KRMD Unlock Forecast - 30 Days FREE Trial $258M -19.8x 15.7x
LMAT Unlock Forecast - 30 Days FREE Trial $1964M 36.8x 5.2x
LNSR Unlock Forecast - 30 Days FREE Trial $122M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $139M -0.6x 5.4x
LUNG Unlock Forecast - 30 Days FREE Trial $67M -4.3x 1.1x
LYRA Unlock Forecast - 30 Days FREE Trial $6M -0.1x 4.6x
MBOT Unlock Forecast - 30 Days FREE Trial $159M -1.3x 2.0x
MCAG Unlock Forecast - 30 Days FREE Trial $33M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $31M x -9.9x
MDAI Unlock Forecast - 30 Days FREE Trial $44M -1.3x -42.3x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.2x 12.2x
MDXG Unlock Forecast - 30 Days FREE Trial $1037M 25.4x 4.3x
MGRM Unlock Forecast - 30 Days FREE Trial $217M -10.7x 25.1x
MHUA Unlock Forecast - 30 Days FREE Trial $450M x 2.7x
MMM Unlock Forecast - 30 Days FREE Trial $88970M 26.2x 19.2x
MMSI Unlock Forecast - 30 Days FREE Trial $4947M 41.8x 3.2x
MODD Unlock Forecast - 30 Days FREE Trial $24M -2.1x 2.8x
NEPH Unlock Forecast - 30 Days FREE Trial $52M 39.1x 6.2x
NMTC Unlock Forecast - 30 Days FREE Trial $35M -1.7x 4.2x
NPCE Unlock Forecast - 30 Days FREE Trial $555M -10.4x 30.0x
NSPR Unlock Forecast - 30 Days FREE Trial $83M -4.3x 1.3x
NUMD Unlock Forecast - 30 Days FREE Trial $2M x x
NVCR Unlock Forecast - 30 Days FREE Trial $1317M -20.8x 3.9x
NXGL Unlock Forecast - 30 Days FREE Trial $15M -6.8x 2.8x
OBIO Unlock Forecast - 30 Days FREE Trial $251M -3.4x 2.5x
ODYY Unlock Forecast - 30 Days FREE Trial $5M x x
OFIX Unlock Forecast - 30 Days FREE Trial $628M -5.8x 1.4x
OSRH Unlock Forecast - 30 Days FREE Trial $18M x 0.2x
OSUR Unlock Forecast - 30 Days FREE Trial $172M 17.1x 0.5x
PAVM Unlock Forecast - 30 Days FREE Trial $9M 0.1x 0.3x
PDEX Unlock Forecast - 30 Days FREE Trial $119M 10.3x 2.9x
PEN Unlock Forecast - 30 Days FREE Trial $11801M 72.0x 8.7x
PETV Unlock Forecast - 30 Days FREE Trial $39M -1.4x 9.3x
PLRZ Unlock Forecast - 30 Days FREE Trial $19M x 1.0x
PLSE Unlock Forecast - 30 Days FREE Trial $901M -2.6x 9.7x
PMI Unlock Forecast - 30 Days FREE Trial $157M x 19.7x
PODD Unlock Forecast - 30 Days FREE Trial $22012M 89.4x 15.9x
PRCT Unlock Forecast - 30 Days FREE Trial $1979M -45.4x 5.2x
PROF Unlock Forecast - 30 Days FREE Trial $199M x 6.2x
PSTV Unlock Forecast - 30 Days FREE Trial $80M -0.3x 15.9x
PYPD Unlock Forecast - 30 Days FREE Trial $62M x 3.0x
RCEL Unlock Forecast - 30 Days FREE Trial $113M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $33M x 15.0x
RMD Unlock Forecast - 30 Days FREE Trial $37441M 26.0x 6.1x
RSMDF Unlock Forecast - 30 Days FREE Trial $3638M 2.6x 0.6x
RTGN Unlock Forecast - 30 Days FREE Trial $60M x x
RVP Unlock Forecast - 30 Days FREE Trial $25M -0.9x 0.3x
SGHT Unlock Forecast - 30 Days FREE Trial $444M -3.7x 6.9x
SIBN Unlock Forecast - 30 Days FREE Trial $842M -14.3x 4.9x
SIGY Unlock Forecast - 30 Days FREE Trial $3M x x
SKIN Unlock Forecast - 30 Days FREE Trial $188M -1.8x 2.9x
SNOA Unlock Forecast - 30 Days FREE Trial $5M -5.6x 1.4x
SNWV Unlock Forecast - 30 Days FREE Trial $282M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $14817M 9.7x 3.0x
SRTS Unlock Forecast - 30 Days FREE Trial $69M 31.6x 1.4x
SSKN Unlock Forecast - 30 Days FREE Trial $8M -8.0x 6.0x
STIM Unlock Forecast - 30 Days FREE Trial $102M -1.0x 3.7x
STME Unlock Forecast - 30 Days FREE Trial $14M x x
STSS Unlock Forecast - 30 Days FREE Trial $86M -2.5x 0.2x
SYK Unlock Forecast - 30 Days FREE Trial $140694M 47.8x 12.0x
TCMD Unlock Forecast - 30 Days FREE Trial $619M 34.1x 3.0x
TELA Unlock Forecast - 30 Days FREE Trial $49M -1.8x 31.4x
TFX Unlock Forecast - 30 Days FREE Trial $5393M 31.0x 1.4x
TLSI Unlock Forecast - 30 Days FREE Trial $351M -3.6x -5.6x
TLSIW Unlock Forecast - 30 Days FREE Trial $62M x -1.9x
TMCI Unlock Forecast - 30 Days FREE Trial $173M -7.5x 1.9x
TNDM Unlock Forecast - 30 Days FREE Trial $1404M -17.1x 10.6x
TNON Unlock Forecast - 30 Days FREE Trial $10M -0.3x 2.0x
UFPT Unlock Forecast - 30 Days FREE Trial $1668M 24.8x 4.1x
USAQ Unlock Forecast - 30 Days FREE Trial $4M x x
UTMD Unlock Forecast - 30 Days FREE Trial $179M 15.4x 1.5x
VERO Unlock Forecast - 30 Days FREE Trial $4M 0.0x 1.4x
VYCO Unlock Forecast - 30 Days FREE Trial $6M x x
WST Unlock Forecast - 30 Days FREE Trial $20149M 41.0x 6.6x
XAIR Unlock Forecast - 30 Days FREE Trial $11M -0.3x 0.9x
XTNT Unlock Forecast - 30 Days FREE Trial $83M -478.8x 1.6x

Frequently Asked Questions - Lucid Diagnostics Inc. Stock Forecast

How accurate are Lucid Diagnostics Inc. stock predictions?

Our AI model shows a 18% Spearman correlation coefficient for LUCD predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Lucid Diagnostics Inc. stock price forecasts?

Our analysis considers Lucid Diagnostics Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Lucid Diagnostics Inc. a good investment in 2025?

Based on our AI analysis, Lucid Diagnostics Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Lucid Diagnostics Inc. forecasts updated?

Lucid Diagnostics Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Lucid Diagnostics Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Lucid Diagnostics Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...